Myelodysplastic Syndromes
Myelodysplastic Syndromes
The latest news, research, and perspectives in myelodysplastic syndromes (MDS). Subtypes of this heterogeneous group of disorders occur when blood-forming cells in the bone marrow become abnormal. Sometimes, MDS precedes acute myeloid leukemia.
Advertisement
Melissa BadamoAcute Lymphoblastic Leukemia | July 7, 2025
Gaps in coordination and collaboration between primary care and oncology may impact long-term survival outcomes for patients.
Andrew MorenoMyelodysplastic Syndromes | July 2, 2025
No new safety signals were observed in this phase 3 trial which compared the combination with placebo plus azacitidine.
Nichole TuckerMyelodysplastic Syndromes | June 28, 2025
Bexmarilimab shows promising responses in high-risk MDS, with up to 85% ORR in the BEXMAB phase 2 study.
Andrew MorenoMyelodysplastic Syndromes | June 26, 2025
The comparative results from a first-of-its-kind healthcare claims database study support this conclusion.
Nichole TuckerMyelodysplastic Syndromes | June 26, 2025
Luspatercept shows longer survival and transfusion independence in ESA-naïve lower-risk MDS, COMMANDS trial.
Idoroenyi Amanam, MDMyelodysplastic Syndromes | July 7, 2025
Dr. Idoroenyi Amanam explains why luspatercept offers new hope for patients with low-risk myelodysplastic syndromes.
Advertisement
Melissa BadamoAcute Myeloid Leukemia | June 24, 2025
SENTI-202, a first-in-class, off-the-shelf, logic-gated CAR-NK cell therapy, is currently being evaluated in a phase 1 trial.
Amer Zeidan, MBBS, MHSMeeting News | June 27, 2025
The phase 1/2 study's safety and efficacy data on bexmarilimab plus azacitidine for high-risk MDS are promising.
Melissa BadamoMyelodysplastic Syndromes | June 10, 2025
Azacitidine plus valproic acid is a safe and feasible maintenance regimen for patients with high-risk AML and MDS after HSCT.
Melissa BadamoMyelodysplastic Syndromes | June 3, 2025
Frontline luspatercept demonstrates superior efficacy compared with ESAs in patients with lower-risk MDS.
Catherine Lai, MD, MPHAcute Lymphoblastic Leukemia | June 3, 2025
100% MRD-negative CR in Ph+ ALL? Dr. Catherine Lai recaps standout abstracts from an ASCO rapid oral session.
Melissa BadamoMyelodysplastic Syndromes | June 2, 2025
Naval Daver, MD, presented on the efficacy and safety of bexmarilimab plus standard-of-care azacitidine for MDS at ASCO 2025.
Nichole TuckerMyelodysplastic Syndromes | June 10, 2025
IME shows strong efficacy in LR-MDS, offering transfusion independence in heavily pretreated, ESA-ineligible patients.
Rahul Banerjee, MD, FACPAcute Myeloid Leukemia | June 30, 2025
Experts discuss early detection in myeloid malignancies, from current challenges to future innovations.
Melissa BadamoAcute Myeloid Leukemia | May 19, 2025
ADP-heptose in the intestines of older individuals accelerates the expansion of pre-leukemic blood cells.
Melissa BadamoAcute Lymphoblastic Leukemia | May 16, 2025
Studies have shown that oncologists are leaving the workforce at increasing rates in association with growing workloads.
Nichole TuckerMyelodysplastic Syndromes | May 13, 2025
Julie Braish, MBBCh, a third-year fellow at MD Anderson, presented data on azacitidine and venetoclax in HR-MDS and CMML.
Andrew MorenoAcute Myeloid Leukemia | May 9, 2025
Presented preclinical model data show significant efficacy against AML cell lines with FLT3, KMT2A, NPM1, and TP53 mutations.
Melissa BadamoAcute Lymphoblastic Leukemia | May 8, 2025
LucyRx’s pharmacy network includes Northwestern Medicine Specialty Pharmacy, Dana Farber Cancer Institute, and more..
Naval Daver, MDMyelodysplastic Syndromes | May 8, 2025
Naval Daver, MD, discusses the latest advancements in the treatment of myelodysplastic syndromes
Advertisement
Advertisement